COVID cash funds a rocky oncology pivot
- BioNTech still makes most revenue from COMIRNATY, its COVID-19 vaccine with Pfizer.
- Management raised 2026 revenue guidance to a range of €1.7 billion to €1.9 billion on BMS collaboration payments.
- The BMS deal for pumitamig brings $3.5 billion of noncontingent cash through 2028.
- The cancer pipeline suffered recent setbacks, with failures in the iNeST and FixVac programs.
- The company faces execution risk as new CEO Guido Oelkers prepares to take over by February 1.
A funded but hard pivot
The bull case is simple. BioNTech turned the COVID-19 vaccine boom into a massive funding base, ending 2025 with about €17.2 billion in cash and investments. That gives the company time to run large oncology trials, including a new Phase III trial for the prostate cancer drug elfetabart, without needing to raise money in a weak market.
The biggest new support is the Bristol Myers Squibb partnership for pumitamig, also called BNT327. BMS paid $1.5 billion upfront, and BioNTech expects $2.0 billion more in noncontingent anniversary payments through 2028. To further free up capital, BioNTech shifted its Roche and Genentech collaboration to a royalty model.
The bear case is that having cash does not make drugs work. Recent data readouts have disappointed. The individualized mRNA platform iNeST missed in advanced melanoma and saw a colorectal cancer trial stopped early due to an overall survival imbalance. The BNT113 vaccine also missed its primary endpoint in head and neck cancer. Furthermore, the lead breast cancer drug T-Pam showed limited benefit and higher toxicity.
The setup is mixed. BioNTech has money, partners, and many shots on goal. It also faces falling COVID-19 revenue, execution risks in its pipeline, and a major leadership transition as Guido Oelkers prepares to replace the founding CEO.
Vaccine cash, cancer spend
BioNTech makes commercial money mainly from COMIRNATY, its COVID-19 vaccine sold with Pfizer. The vaccine market is now seasonal and smaller than during the pandemic. Management expects 2026 revenue between €1.7 billion and €1.9 billion, supported in part by one-time payments. The core cash cow is steadily declining.
The company is spending that vaccine cash on a multi-technology cancer pipeline. It started as an mRNA leader, but it now works heavily on bispecific antibodies and antibody-drug conjugates. Antibody-drug conjugates are targeted cancer drugs that link an antibody to a cell-killing payload, representing a massive portion of the current R&D budget.
Partnerships change the funding math. BioNTech recognized €613 million of out-licensing revenue in late 2026 from the pumitamig partnership. The company also shifted its Genentech cost-sharing deal to a royalty model to push future R&D costs onto its partner.
The model breaks if late-stage cancer trials fail, regulators ask for more data, or manufacturing cannot scale. BioNTech reports as one operating segment, but economically the company is moving from one shrinking commercial vaccine product toward several still-unproven oncology products.
What BioNTech is betting on
COMIRNATY
COMIRNATY is the COVID-19 vaccine sold with Pfizer. It still funds much of the company, but 2026 guidance assumes significantly lower COVID-19 vaccine revenue.
Pumitamig, BNT327
Pumitamig is a PD-L1 and VEGF bispecific antibody. BioNTech is advancing it into Phase III combinations with Gilead's TROP2 ADC.
T-Pam, BNT323
BNT323 is a HER2 antibody-drug conjugate. It showed limited benefit in breast cancer, and a BLA filing in endometrial cancer moved into 2026 after the FDA asked for more analysis.
Elfetabart, BNT324
Elfetabart is a B7-H3 antibody-drug conjugate. It recently entered a Phase III trial for metastatic castration-resistant prostate cancer.
iNeST
iNeST is BioNTech's individualized mRNA cancer vaccine platform. It saw a recent colorectal cancer trial discontinued due to an overall survival imbalance.
FixVac, BNT113
FixVac is an off-the-shelf mRNA cancer vaccine approach. BNT113 missed its first dual primary endpoint in head and neck cancer.
One segment, three revenue buckets
BioNTech reports one operating and reporting segment. The mix shown here uses the fiscal 2025 revenue categories disclosed in the 2025 Form 20-F, as 2026 segment actuals remain pending.
What could go wrong
COVID revenue keeps shrinking
High impact · High oddsCOVID-19 vaccine demand is fading faster than expected. Management sees weak global demand and Germany using old inventory. If sales keep dropping, the cash bridge to oncology gets thinner.
iNeST and mRNA platforms fail to translate
Medium impact · High oddsThe individualized mRNA vaccine iNeST saw a colorectal cancer trial stopped early due to an overall survival imbalance, adding to a prior miss in melanoma. The off-the-shelf BNT113 also missed its progression-free survival endpoint. The core mRNA technology faces serious clinical headwinds in oncology.
BNT323 faces FDA and efficacy risk
High impact · Medium oddsBioNTech pushed the BLA for BNT323 in endometrial cancer into 2026 after FDA discussions about additional data needs. Furthermore, the drug showed limited benefit and higher toxicity in a recent breast cancer update, raising questions about its broader potential.
Pumitamig must prove itself in Phase 3
High impact · Medium oddsThe BMS partnership brings large noncontingent cash, but pumitamig still has to succeed in broad Phase 3 testing. The market may give little credit to this program until randomized data are clear.
Leadership handoff creates uncertainty
Medium impact · Medium oddsCo-founders Ugur Sahin and Ozlem Tureci are stepping away to start a new venture. The company named Guido Oelkers as the new CEO, taking over by February 1. The risk is that a hard oncology pivot loses momentum during a major transition at the top.
In one breath
Is BioNTech still mainly a COVID vaccine company?
Commercially, yes. Most recent revenue comes from COVID-19 vaccine sales. Strategically, the company is trying to become an oncology company, with about 90% of current R&D spend going to cancer drugs.
Why does the BMS deal matter for BioNTech?
The BMS deal helps pay for a much larger pumitamig trial program. It gives BioNTech $1.5 billion upfront and $2.0 billion in noncontingent anniversary payments through 2028, while sharing future costs and economics.
What is the next big BioNTech catalyst?
Investors should watch the 2026 BNT323 filing path, the Phase 3 prostate cancer trial for elfetabart, and randomized data from pumitamig studies. The handover to incoming CEO Guido Oelkers on February 1 is also a major event.
Does BioNTech have enough cash to fund the pivot?
BioNTech ended 2025 with about €17.2 billion in cash, cash equivalents, and security investments. That is a strong cushion, but it does not remove clinical, regulatory, or execution risk.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near BioNTech SE in Finn's Biotechnology industry ranking.

